Related Experiment Video

Updated: Feb 9, 2026

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
10:03

Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes

Published on: November 11, 2016

10.3K

An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells

Atsushi Sakamoto1, Kazunori Kato2,3, Toshio Hasegawa1

  • 1Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Anticancer Research
|June 1, 2018
PubMed
Abstract

Insights

Antibodies targeting EPH receptor A2 (EPHA2) show promise for melanoma treatment. One antibody, SHM16, inhibited cancer cell migration and, when conjugated to toxins, caused significant cell death.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • EPH receptor A2 (EPHA2) is overexpressed in aggressive human cancers.
  • EPHA2 is a potential target for antibody-based cancer therapies.

Purpose of the Study:

  • To evaluate the therapeutic potential of EPHA2 antibodies against melanoma.
  • To investigate EPHA2 as a therapeutic target in melanoma treatment.

Main Methods:

  • Generated three monoclonal antibodies (mAbs) against EPHA2.
  • Assessed EPHA2 expression using flow cytometry.
  • Evaluated anti-metastatic effects via wound scratch and invasion assays.
  • Tested immunotoxins composed of EPHA2 mAbs conjugated to toxins.

Main Results:

  • All tested melanoma cell lines expressed EPHA2.
  • One EPHA2 mAb, SHM16, inhibited melanoma cell migration and invasion, similar to its natural ligand ephrin-A1.
  • SHM16-based immunotoxins demonstrated significant melanoma cell growth inhibition and cytotoxicity.

Conclusions:

  • EPHA2 is a promising therapeutic target for melanoma.
  • An agonistic antibody to EPHA2, SHM16, exhibits significant anti-melanoma potential.
  • EPHA2-targeted immunotoxins offer a viable therapeutic strategy for melanoma.
Keywords:
EPHA2immunotoxininvasionmelanomamonoclonal antibody

More Related Videos

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation07:00

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation

Published on: August 23, 2018

6.6K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.4K

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
995
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.7K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.1K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.7K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K